FDA panel to discuss Aranesp, review ESAs in kidney disease
This article was originally published in Scrip
Executive Summary
The US FDA's cardiovascular and renal drugs advisory will meet on 18 October to consider issues surrounding the use of erythropoiesis-stimulating agents (ESAs), including Amgen's Aranesp (darbepoetin-alfa) and Amgen/Johnson & Johnson's Epogen/Procrit (epoetin-alfa), to treat anaemia that may occur as a result of chronic kidney disease.